REACH: non-regulatory announcement
24 January
2025
SOLVONIS
THERAPEAUTICS PLC
("Solvonis" or the "Company")
Investor
Presentation
Solvonis Therapeutics plc (LON: SVNS), an
innovative biotechnology company co-developing therapeutics for
mental health disorders, is pleased to announce that the
Company will be presenting at MelloMonday on
Monday 27 January 2025 which will take
place as a webinar via Zoom. Anthony Tennyson, CEO, will be
presenting and will take questions during the
event.
For further information or if you would like to
attend, please visit:
https://melloevents.com/mm270125/
where you can register for a free
ticket using the code SHME100.
Enquiries:
Solvonis
Therapeutics plc
Anthony Tennyson, CEO & Executive Director
Email: anthony@solvonis.com
Allenby Capital (Financial Adviser and Broker)
+44 (0) 20 3328 5656
Nick Naylor / Liz
Kirchner (Corporate Finance) | Guy McDougall (Sales)
About Solvonis Therapeutics plc
Solvonis Therapeutics plc is an innovative
biotechnology company focused on developing intellectual
property relating to the treatment of mental health and substance
use disorders, and the co-development of therapeutics for mental
health disorders. Our mission is to improve outcomes
for individuals suffering from these conditions, with an initial
focus on trauma-related mental health disorders, such as PTSD,
which affected approximately 13 million adults in the U.S. in 2020,
with the Company estimating a current affected population
of 20 million across the US, UK and key EU markets.
www.solvonis.com
| LinkedIn
| X (formerly
Twitter)
About Reach
announcements
This is an RNS Reach announcement. Reach is an
investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute media only
/ non-regulatory news releases into the public domain.
Information required to be notified under the AIM Rules for
Companies, Market Abuse Regulation or other regulation would be
disseminated as an RNS regulatory announcement and not on
Reach.
